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Background: Tumor cells produce various cytokines and chemokines that attract leukocytes. Leukocytes can
amplify parenchymal innate immune responses, and have been shown to contribute to tumor promotion.
Neutrophils are among the first cells to arrive at sites of inflammation, and the increased number of
tumor-associated neutrophils is linked to poorer outcome in patients with lung cancer.
Results: We have previously shown that COPD-like airway inflammation promotes lung cancer in a K-ras mutant
mouse model of lung cancer (CC-LR). This was associated with severe lung neutrophilic influx due to the increased level
of neutrophil chemoattractant, KC. To further study the role of neutrophils in lung tumorigenesis, we depleted
neutrophils in CC-LR mice using an anti-neutrophil antibody. This resulted in a significant reduction in lung tumor
number. We further selectively inhibited the main receptor for neutrophil chemo-attractant KC, CXCR2. Similarly, this
resulted in suppression of neutrophil recruitment into the lung of CC-LR mice followed by significant tumor reduction.
Neutrophil elastase (NE) is a potent elastolytic enzyme produced by neutrophils at the site of inflammation. We crossed
the CC-LR mice with NE knock-out mice, and found that lack of NE significantly inhibits lung cancer development.
These were associated with significant reduction in tumor cell proliferation and angiogenesis.
Conclusion: We conclude that lung cancer promotion by inflammation is partly mediated by activation of the
IL-8/CXCR2 pathway and subsequent recruitment of neutrophils and release of neutrophil elastase. This provides a
baseline for future clinical trials using the IL-8/CXCR2 pathway or NE inhibitors in patients with lung cancer.
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Lung cancer is the leading cause of cancer death world-
wide accounting for 29% of all male and 26% of all female
cancer deaths in 2012 [1]. Cigarette smoking (CS) is the
principal cause of lung cancer, and CS induced lung can-
cer is characterized by a deregulated inflammatory micro-
environment [2]. In addition, the association between
chronic obstructive pulmonary disease (COPD), an in-
flammatory disease of the lung, and lung cancer has been
demonstrated in population-based studies [3,4]. Smokers* Correspondence: smoghadd@mdanderson.org
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reproduction in any medium, provided the orwith COPD have an increased risk of lung cancer com-
pared to smokers with comparable cigarette exposure but
without COPD [5,6]. Importantly, among former smokers
with COPD, even following withdrawal of cigarette smoke,
inflammation persists and lung function continues to de-
teriorate as does the increased risk of lung cancer [7].
These facts suggest a strong link between airway inflam-
mation and lung cancer promotion.
Tumor cells produce various cytokines and chemokines
that attract leukocytes including neutrophils, dendritic
cells, macrophages, lymphocytes and mast cells [6]. It is
becoming increasingly clear that tumor-associated neutro-
phils (TANs) play a major role in cancer promotion [8].
During immune responses, neutrophils are among the firsttd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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number of TANs is linked to poorer outcomes in patients
with bronchioloalveolar carcinoma [9], and many patients
with advanced cancer show high levels of blood neutro-
phils [10]. Furthermore, in histopathologic specimens of
distal lung and in bronchoalveolar lavage fluid (BALF)
from COPD patients, neutrophils are prominent [11,12],
and shown to cause COPD progression [13]. We have
previously established a COPD-like mouse model of air-
way inflammation induced by repetitive exposure to an
aerosolized lysate of non-typeable Haemophilus influenzae
(NTHi) [11], which is the most common bacterial colon-
izer of airways in COPD patients [14]. Then we showed
that this type of airway inflammation promotes lung can-
cer in a K-ras mutant mouse model of lung cancer (CC-
LR) [15]. This was associated with severe neutrophilic in-
flux due to an increased level of neutrophil chemoattract-
ant, KC, which was partially inhibited by using a natural
non-specific anti-inflammatory agent, curcumin, and re-
sulted in significant tumor suppression [16]. Therefore, we
further dissected the role of neutrophils in lung tumori-
genesis by selectively targeting neutrophils, its chemokine
receptor (CXCR2) and its specific enzyme (neutrophil
elastase). Neutrophil depletion, CXCR2 inhibition, and
lack of neutrophil elastase (NE) all resulted in significant
tumor reduction in our K-ras mutant mouse model of
lung cancer.
Results
Neutrophil depletion inhibits lung cancer promotion
To test the effect of neutrophil depletion on lung cancer
development, we treated the CC-LR mice with mLy-6G
Ab 5 mg/kg i.p. twice a week. Two groups (N = 8) of 10-
week-old CC-LR mice were treated with mLy-6G Ab for
4 weeks, with one of these groups exposed to the NTHi
lysate once a week for 4 weeks for induction of a COPD-
type inflammatory lung phenotype. Two other (N = 8)
groups of mice were treated with isotype control while
one of them was exposed to NTHi lysate. All groups were
sacrificed one day after the fourth NTHi exposure.
We and others have shown that expression of K-
rasG12D within the airway epithelium of mice induces
the production of chemokines which leads to the accu-
mulation of inflammatory cells, particularly macro-
phages and neutrophils, within the lung [15,17,18]. In
the BALF of non-NTHi exposed Ab treated CC-LR
mice, the total white blood cells decreased mostly
due to complete depletion of neutrophils by the mLy-
6G Ab (Figure 1A). The macrophage and lymphocyte
counts were slightly reduced as well, because the mLy-
6G Ab can non-specifically affect Gr-1+ monocytes/
macrophages and lymphocyte subpopulations [19]. Sur-
prisingly, the mLy-6G Ab was not able to completely
deplete the neutrophils from the BALF of CC-LR miceafter repetitive NTHi exposure, while the macrophages
had a 2.4 reduction (Figure 1B).
Secreted cytokines and chemokines could both cause
the recruitment of leukocytes and also help to identify
the leukocyte phenotypes. Treatment with mLy-6G Ab
in CC-LR mice non-exposed or exposed to NTHi re-
sulted in a reduction in the level of neutrophil chemo-
attractant, KC in BALF (Table 1 and data not shown)
which is consistent with reduced numbers of inflamma-
tory cells in the BALF. CCL2 and CCL5 are phenotypic
markers for TANs [20], which are protumorigenic (N2
phenotype). mLy-6G Ab inhibited these N2 type chemo-
kine particularly CCL5 secretions (Table 1 and data not
shown). Low iNOS and high arginase 1 expressions are
two other important indicators of N2 type neutrophils
[20-22]. Real-time Q-PCR analysis of the RNA extracted
from the whole lung of CC-LR mice showed that treat-
ment with mLy-6G Ab reduced the relative expression
of arginase 1 in presence or absence of NTHi exposure
(Figure 1C), while it had the opposite effect on relative
expression of iNOS (Additional file 1: Figure S1A). This
was associated with decreased protein expression of ar-
ginase 1 in western blot (WB) analysis of the whole lung
from CC-LR mice treated with mLy-6G Ab (Figure 1C).
Co-staining of lung tissue with Ly6G and arginase 1Abs
showed the expression of arginase 1 in neutrophils
(Additional file 1: Figure S1B). Levels of other essential
proinflammatory cytokines (IL-6, IL-17, TGF-β) were
slightly suppressed by mLy-6G Ab (Table 1 and data not
shown). These results indicate that mLy-6G Ab could
have an effect on tumor promotion by inhibiting neutro-
phil infiltration into the tumor microenvironment. Fur-
thermore, mLy-6G Ab might be able to edit neutrophils
phenotype from a pro-tumor phenotype (N2) toward an
anti-tumor phenotype (N1).
The effects of the neutrophil depletion using mLy-6G
Ab on lung tumor promotion was analyzed by determin-
ing the number of tumors visible on the pleural surface of
the lungs from CC-LR mice. mLy-6G Ab significantly
reduced the tumor numbers on the lung surface of CC-LR
mice not exposed to NTHi lysate by ~68% (3.2-fold, 51 ± 2
without mLy-6G versus 16 ± 2 with mLy-6G) and after
NTHi exposure by ~80% (4.9-fold, 108 ± 11 without
mLy-6G versus 22 ± 2 with mLy-6G) (Figure 1E). Histo-
pathologic analysis showed that mLy-6G Ab treatment
prevented lung cancer progression, with most of the lung
tumors remaining at the early stage with less inflammatory
cell infiltration both in the presence and absence of NTHi
exposure (Figure 1F).
We further stained for lung parenchymal and tumor in-
filtrating neutrophils using P40 Ab by IHC. We did not
find any neutrophils infiltrating the lung of Ab treated
non-NTHi exposed CC-LR mice compared to the lung of
non-Ab treated mice (data not shown). NTHi exposure
Figure 1 Effect of treatment with anti-neutrophil antibody on lung inflammation and tumor promotion. (A) Total and lineage-specific
leukocyte number in BALF of CC-LR mice treated or non-treated with mLy-6G Ab at the age of 14 weeks (mean ± SE; * = P ≤ 0.05 for CC-LR vs
CC-LR plus mLy-6G). (B) Total and lineage-specific leukocyte number in BALF of NTHi-exposed CC-LR mice treated or non-treated with mLy-6G
Ab collected 1 day after last NTHi aerosol exposure at the age of 14 weeks (mean ± SE; * = P≤ 0.05 for CC-LR vs CC-LR plus mLy-6G with NTHi
exposure). (C) Real-time Q-PCR expression analysis of arginase 1 on the RNA extracted from whole lung tissue (normalized to GAPDH expression
level, mean ± SE; * = P≤ 0.05 for CC-LR vs CC-LR with NTHi exposure; # = P ≤ 0.05 for CC-LR with NTHi exposure vs CC-LR with NTHi exposure plus
mLy-6G treatment). (D) Western blot analysis of arginase 1 on the protein extracted from whole lung tissue. (E) Lung surface tumor number after
mLy-6G Ab treatment in NTHi exposed or non-exposed 14-week-old CC-LR mice. (mean ± SE; * = P≤ 0.05 for CC-LR vs CC-LR plus mLy-6G
treatment; # = P≤ 0.05 for CC-LR with NTHi exposure vs CC-LR with NTHi exposure plus mLy-6G treatment). (F) Histopathological appearance of
lung tissue after treatment with mLy-6G Ab in NTHi exposed or non-exposed CC-LR mice. (4× magnification, scale bar = 50 mm, applicable to
all panels).
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cantly (1.6 fold) decreased by mLy-6G Ab treatment
(Figure 2A). Interestingly, there were more neutrophils
infiltrated in the tumor site than the normal lung tissue,
and these neutrophils in the tumor site decreased 2.1 fold
in response to treatment with mLy-6G Ab (Figure 2B).In order to evaluate the mechanism of tumor suppres-
sion by mLy-6G Ab, we studied the rate of proliferation,
angiogenesis and apoptosis. The relative number of cells
showing positive staining for the cell proliferation
marker, Ki-67, was measured in tumor tissues from the
four groups by immunohistochemistry (Figure 2C). The
Table 1 Cytokines and chemokines in bronchoalveolar
fluid of CC-LR mice
Cytokine Ctrl* +mLy-6G +SBZ
IL-6 4.66 ± 1.73 1.31 ± 1.39 1.34 ± 1.02
TGF-β 303.31 ± 99.50 210.55 ± 148.65 154.60 ± 134.40
IL-17 1.47 ± 1.95 0.55 ± 0.66 ND†
KC 9.48 ± 4.40 3.25 ± 1.57 5.41 ± 5.39
CCL5/RANTES 2.78 ± 0.73 0.58 ± 0.69 0.93 ± 0.26
*All data are means (±SEM), and there are no significant statistical differences
(P>0.05).
†ND, not detected.
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67 in tumor tissues compared with non-Ab treated mice
from both NTHi exposed and unexposed control groups
(Figure 2D). Interestingly, in the NTHi exposed group, the
infiltrating neutrophils also showed a high level of prolifer-
ation, suggesting the recruitment of immature neutrophils
to the tumor site which are still going through proliferation
(Figure 2D, Additional file 1: Figure S1C). This was sup-
pressed with mLy-6G Ab treatment. In order to study the
effect of mLy-6G Ab on angiogenesis, we performed the
CD31 immunostaining, which is expressed on a large por-
tion of endothelial cells [23]. CD31 expression followed the
same pattern as Ki-67 (Figure 2E). The percentage of posi-
tive cells in the Ab treated group decreased (78%) com-
pared to the control group in the absence of NTHi
exposure. There was no significant change between the Ab
treated and non-treated groups after NTHi exposure
(Figure 2F). IHC analysis of tumor cell using cleaved
caspase-3 marker did not show apoptosis among different
groups (data not shown).
Selective CXCR2 inhibition suppresses lung
cancer promotion
As described above, KC is a very important chemo attract-
ant for neutrophils. It could bind to the CXCR2 receptor,
which will cause neutrophil recruitment [24], hence mak-
ing it a good target for lung cancer treatment. We treated
CC-LR mice with a selective CXCR2 inhibitor, SB332235Z
(SBZ) 50 mg/kg orally, twice daily by gavage. Two groups
(N = 8) of 10-week-old CC-LR mice were treated with
SBZ for 4 weeks, with one of these groups exposed to
NTHi lysate once a week for 4 weeks. Two other groups
(N = 8) of mice were treated with vehicle control while
one of them was exposed to NTHi lysate. All groups were
sacrificed one day after the fourth NTHi exposure. Ana-
lysis of the BALF from SBZ treated non-NTHi exposed
mice showed significant inhibition of neutrophil recruit-
ment (Figure 3A). However, it did not effectively suppress
neutrophil recruitment after 4 weeks of NTHi exposure
(Figure 3B). Similarly, BALF KC levels also decreased by
SBZ treatment in the non-NTHi exposed group, while
remaining high in the NTHi exposed group (Table 1 anddata not shown). Meanwhile, the levels of proinflamma-
tory cytokines were suppressed by SBZ only in the non-
NTHi group (Table 1 and data not shown). This was
associated with decreased arginase 1 mRNA expression
(Figure 3C) and increased iNOS mRNA expression
(Additional file 2: Figure S2A) in the whole lung of CC-
LR mice after SBZ treatment similar to what we found
in samples treated with mLy-6G Ab. Furthermore, WB
analysis of the whole lung from CC-LR mice treated
with SBZ showed decreased protein expression of argi-
nase 1 (Figure 3D).
Treatment with this selective CXCR2 antagonist reduced
the tumor number on the lung surface of CC-LR mice not
exposed to NTHi lysate by ~67% (3-fold, 54 ± 5 without
SBZ versus 18 ± 2 with SBZ) and after NTHi exposure
by ~23% (1.3-fold, 108 ± 11 without SBZ versus 83 ± 21
with SBZ) (Figure 3E). Histopathologic analysis of lung tis-
sue from SBZ treated CC-LR mice showed that CXCR2 in-
hibition prevented lung cancer progression, with most of
the lung tumors remaining at the early stage with less in-
flammatory cell infiltration both in the presence and ab-
sence of NTHi exposure (Figure 3F).
IHC staining of the lung tissue from mice treated with
SBZ with P40 antibody showed similar results as the mice
treated with mLy-6G Ab (Figure 4A). Not many infiltrat-
ing neutrophils in the lung parenchyma were found in
both non-NTHi groups. However, there was a 1.8 fold re-
duction in neutrophil infiltration by SBZ treatment in
NTHi group (Figure 4B). There were more neutrophils
found in the tumor site than the normal lung tissue, and
infiltrating neutrophils in the tumor site decreased 1.6 fold
in response to SBZ treatment (Figure 4B).
To evaluate the effect of SBZ on cell proliferation, Ki-67
was measured in tumor tissues from the four groups by
immunohistochemistry (Figure 4C). CXCR2 inhibition
with SBZ effectively suppressed the expression of Ki-67 in
tumor tissues compared to both NTHi exposed and non-
exposed control groups. Again, high numbers of prolifer-
ating neutrophils were found infiltrated in the tumor site
(Figure 4D, Additional file 2: Figure S2B). To study the
effect of CXCR2 inhibition on tumor angiogenesis, CD31
IHC staining was performed (Figure 4E). SBZ treatment
resulted in a 53% decrease in CD31 expression in the non-
NTHi exposed group, and a 68% decrease in CD31
expression in the NTHi exposed group compared to con-
trols (Figure 4F). Similar to mLy-6G Ab treated groups,
no apoptotic tumor cells was found after SBZ treatment
(data not shown).
Lack of neutrophil elastase (NE) inhibits lung
cancer promotion
NE is an elastolytic enzyme, which is a potential regulator
of the inflammatory process [25]. Many literatures verified
that NE contributes to different stages of tumorigenesis
Figure 2 Immunohistochemical analysis of lung tissue after treatment with anti-neutrophil antibody. (A) Labeling with P40 Ab to detect
infiltrating neutrophils in the non-tumoral area and tumoral area of the lung in CC-LR mice with or without mLy-6G treatment in presence of
NTHi (20× magnification, scale bar = 50 mm, applicable to all panels). (B) Quantitative analysis of P40 positive staining in the non-tumoral area
and tumoral area of the lung in CC-LR mice with or without mLy-6G treatment in the presence of NTHi (mean ± SE; * = P≤ 0.05 for CC-LR with
NTHi exposure vs CC-LR with NTHi exposure plus mLy-6G treatment in non-tumoral area; # = P≤ 0.05 for CC-LR with NTHi exposure vs CC-LR with
NTHi exposure plus mLy-6G treatment in tumoral area). (C) Representative photomicrographs of Ki-67 positive cells in lung tissue of CC-LR mice
with or without mLy-6G treatment in the presence or absence of NTHi (40× magnification, scale bar = 50 mm, applicable to all panels).
(D) Quantitative analysis of Ki-67 positive staining in lung tissue from CC-LR mice with or without mLy-6G in the presence or absence of
NTHi exposure (mean ± SE; * = P ≤ 0.05 for CC-LR vs CC-LR plus mLy-6G treatment, # = P ≤ 0.05 for CC-LR with NTHi exposure vs CC-LR
with NTHi exposure plus mLy-6G treatment). (E) Representative photomicrographs of CD31 positive cells in lung tissue of CC-LR mice
with or without mLy-6G treatment in the presence or absence of NTHi (20× magnification, scale bar = 50 mm, applicable to all panels).
(F) Quantitative analysis of CD31 positive staining in lung tissue of CC-LR mice with or without mLy-6G in the presence or absence of
NTHi exposure (mean ± SE; * = P ≤ 0.05 for CC-LR vs CC-LR plus mLy-6G treatment).
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tively in the development of COPD [27] by activating pro-
teolytic cascades. NE knock out (KO) mice were crossed
with CC-LR mice to generate mice with activating mutant
K-ras in the airway epithelium with global lack of NE (CC-LR-NEKO). Lack of NE slightly changed the BALF inflam-
matory cell component of the CC-LR mice, mostly macro-
phages (Figure 5A). However, it significantly inhibited
lung cancer development by ~43% (1.7-fold, 53 ± 5 in CC-
LR vs 31 ± 4 in CC-LR-NEKO) (Figure 5B). This was
Figure 3 Effect of treatment with a selective CXCR2 inhibitor on lung inflammation and tumor promotion. (A) Total and lineage-specific
leukocyte number in BALF of CC-LR mice treated or non-treated with SBZ (selective CXCR2 inhibitor) at the age of 14 weeks (mean ± SE; * = P≤ 0.05
for CC-LR vs CC-LR plus SBZ). (B) Total and lineage-specific leukocyte number in BALF of NTHi-exposed CC-LR mice treated or non-treated with SBZ
collected 1 day after last NTHi aerosol exposure at the age of 14 weeks. (C) Real-time Q-PCR analysis of RNA extracted from whole lung tissue for
relative mRNA expression of arginase 1 (normalized to GAPDH expression level, mean ± SE; * = P≤ 0.05 for CC-LR vs CC-LR plus SBZ treatment in
figure D, # = P≤ 0.05 for CC-LR with NTHi exposure versus CC-LR with NTHi exposure plus SBZ treatment). (D) Western blot analysis of arginase 1 on
the protein extracted from whole lung tissue. (E) Lung surface tumor number after SBZ treatment in NTHi exposed or unexposed CC-LR
mice. (mean ± SE; * = P ≤ 0.05 for CC-LR vs CC-LR plus SBZ treatment, # = P ≤ 0.05 for CC-LR with NTHi exposure vs CC-LR with NTHi
exposure plus SBZ treatment). (F) Histopathological appearance of lung tissue after treatment with SBZ in NTHi exposed or unexposed
CC-LR mice (4× magnification, scale bar = 50 mm, applicable to all panels).
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(Figure 5D). There were no changes in tumor numbers
and inflammatory cell infiltration of NTHi exposed CC-
LR-NEKO mice (Additional file 3: Figure S3A, and S3B),
suggesting roles for other recruited inflammatory cells,
such as macrophages and their products (e.g. macrophage
elastase) in promotion of lung cancer by COPD-type air-
way inflammation.Histopathologic study of the lung from CC-LR-NEKO
mice showed that absence of NE not only caused less
tumor number but also it delayed lung cancer progression
from early stage hyperplastic lesions to advanced adenoma
and adenocarcinoma (Figure 5C). This was not the case for
NTHi exposed CC-LR-NEKO mice compared to the NTHi
exposed CC-LR mice (Additional file 3: Figure S3B). IHC
analysis for tumor cell proliferation showed less Ki-67
Figure 4 Immunohistochemical analysis of lung tissue after treatment with selective CXCR2 inhibitor. (A) Labeling with P-40 Ab to detect
infiltrating neutrophils in non-tumoral area and in tumoral area in the lung of CC-LR mice with or without SBZ treatment in the presence of NTHi
(20× magnification, scale bar = 50 mm, applicable to all panels). (B) Quantitative analysis of P-40 positive staining (mean ± SE; * = P≤ 0.05 for CC-LR with
NTHi exposure vs CC-LR with NTHi exposure plus SBZ treatment in non-tumoral area; # = P≤ 0.05 for CC-LR with NTHi exposure vs CC-LR with NTHi
exposure plus SBZ treatment in tumoral area). (C) Representative photomicrographs of Ki-67 positive cells in lung tissue of CC-LR mice with or without
SBZ treatment in presence or absence of NTHi (40× magnification, scale bar = 50 mm, applicable to all panels). (D) Quantitative analysis of Ki-67 positive
staining (mean ± SE; * = P≤ 0.05 for CC-LR vs CC-LR plus SBZ treatment, # = P≤ 0.05 for CC-LR with NTHi exposure vs CC-LR with NTHi exposure plus
SBZ treatment). (E) Representative photomicrographs of CD31 positive cells in lung tissue of CC-LR mice with or without SBZ treatment in presence or
absence of NTHi (20× magnification, scale bar = 50 mm, applicable to all panels). (F) Quantitative analysis of CD31 positive staining (mean ± SE;
* = P≤ 0.05 for CC-LR vs CC-LR plus SBZ treatment, # = P≤ 0.05 for CC-LR with NTHi exposure vs CC-LR with NTHi exposure plus SBZ treatment).
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NEKO mice (Figure 5E and F). In addition, there was
significant decrease (48%) in the number of CD31 posi-
tive cells in the CC-LR-NEKO compared to CC-LR
group (Figure 5G and H), which indicates less angio-
genesis in CC-LR-NEKO mice. Reduction of VEGF
level in the BALF (Figure 5I) and less lung tissue VEGFpositive staining (Figure 5J) in CC-LR-NEKO mice fur-
ther verify the effects of NE on angiogenesis. Interest-
ingly, we found a 1.2 fold increase in the number of
cleaved-caspase-3 expressing cells in CC-LR-NEKO
compared to control CC-LR mice (Figure 5K) with
most of apoptosis happening in the early stage tumor
sites (Figure 5L).
Figure 5 (See legend on next page.)
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Figure 5 Effect of neutrophil elastase (NE) depletion on lung tumor promotion. (A) Total and lineage-specific leukocyte number in BALF of
CC-LR mice and CC-LR-NEKO are shown (mean ± SE; * = P ≤ 0.05). (B) Lung surface tumor number of CC-LR and CC-LR-NEKO mice (mean ± SE;
* = P≤ 0.05 for CC-LR vs CC-LR-NEKO mice). (C) Histopathological appearance of lung tissue for CC-LR and CC-LR-NEKO (4× magnification, scale
bar = 50 mm, applicable to all panels). (D) Level of IL-6 and TGF-β in BALF of CC-LR and CC-LR-NEKO mice (mean ± SE, * = P≤ 0.05). (E) Quantitative
analysis of Ki-67 positive staining in lung tissue of CC-LR and CC-LR-NEKO mice (mean ± SE; * = P≤ 0.05). (F) Representative photomicrographs of Ki-67
positive cells in lung tissue of CC-LR and CC-LR-NEKO mice (40× magnification, scale bar = 50 mm, applicable to all panels). (G) Quantitative analysis of
CD31 positive staining in lung tissue of CC-LR and CC-LR-NEKO mice (mean ± SE; * = P≤ 0.05). (H) Representative photomicrographs of CD31 positive
cells in lung tissue of CC-LR and CC-LR-NEKO mice (20× magnification, scale bar = 50 mm, applicable to all panels). (I) Expression level of the VEGF in
BALF of CC-LR and CC-LR-NEKO mice (mean ± SE, * = P≤ 0.05). (J) Representative photomicrograph of VEGF positive cells in lung tissue of CC-LR and
CC-LR-NEKO mice (20× magnification, scale bar = 50 mm, applicable to all panels). (K) Quantitative analysis of cleaved-caspase-3 positive staining in
lung tissue of CC-LR and CC-LR-NEKO mice (mean ± SE; *P≤ 0.05). (L) Representative photomicrographs of cleaved-caspase-3 positive cells in lung
tissue of CC-LR and CC-LR-NEKO mice (20× magnification, scale bar = 50 mm, applicable to all panels).
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Tumor-induced inflammation is now a cancer hallmark,
and it is considered an enabling characteristic due to its
contributions to the acquisition of core hallmark capabil-
ities [28,29]. Tumors are complex tissues composed of mul-
tiple distinct cell types that interact with each other. The
recruited stromal and inflammatory cells, which form the
tumor microenvironment, are active participants in tumori-
genesis and significantly influence most of the cancer hall-
marks in the malignant cancer cells. In summary, the
presence of these stromal and inflammatory cells within the
tumor microenvironment is associated with enhanced
tumor progression, cancer cell growth and spread, angio-
genesis, invasion and tumor immunosuppression [30].
Many environmental causes and risk factors for cancer
are associated with chronic inflammation. According to
epidemiological studies, up to 20% of cancers are linked to
chronic infections and inflammation [31]. Cigarette smok-
ing generates an inflammatory microenvironment which
can promote lung cancer [2]. On the other hand, COPD,
which is a disorder characterized by an abnormal local
and systemic inflammatory response, is also strongly asso-
ciated with lung cancer [32]. In histopathologic specimens
of distal lung and in BALF from COPD patients, neutro-
phils and macrophages are prominent [33]. Neutrophils
make up a significant portion of the inflammatory cell in-
filtrate found in a wide variety of murine models and hu-
man cancers [34,35]. They are among the first cells to
arrive at sites of inflammation and, as mentioned before,
the increased number of TANs is linked to poorer out-
comes in patients with lung cancer. Neutrophils are
present within the alveolar airspaces and within the
tumor parenchyma during neoplastic development in a
urethane-induced mouse model of lung cancer [36]. We
have previously shown that bacterial (NTHi) lysate in-
duced COPD-like airway inflammation promotes lung
cancer in a K-ras mutant mouse model of lung cancer
(CC-LR) [15]. This was associated with severe neutrophilic
influx due to the increased level of neutrophil chemo-
attractant, KC. Furthermore, we and others found that K-
ras mutation per se induces an inflammatory tumormicroenvironment predominated by neutrophils and mac-
rophages [15,17]. In this study, we provided more evidence
to support the essential role for neutrophils in lung cancer
promotion.
mLy-6G Ab is used to deplete neutrophils in murine
disease models. It binds to Ly6G, which is present on neu-
trophils, and to Ly6C, which is expressed on neutrophils,
dendritic cells, and subpopulations of lymphocytes and
monocytes [19]. In our study, depletion of neutrophils by
mLy-6G Ab suppressed lung tumor promotion which was
associated with decreased tumor cell proliferation and
angiogenesis. Similar to tumor associated macrophages
(TAMs), TANs also can be divided into an antitumori-
genic (N1) phenotype and a protumorigenic (N2) pheno-
type [20]. Analysis of cytokines and chemokines in BALF
of CC-LR mice showed suppression of proinflammtory cy-
tokines (IL-6, IL-17, TGF-β) by mLy-6G, with further in-
hibition of N2 type cytokines and molecules (CCL5,
arginase 1). Surprisingly, mLy-6G Ab was not able to sup-
press the number of neutrophils in BALF of NTHi-
exposed mice which can imply that there exists a pool of
neutrophil that can be mobilized. However, mLy-6G Ab
reduced the numbers of macrophages in the BALF and
the number of neutrophils infiltrated in the lung paren-
chyma. Interestingly, many of these infiltrating neutrophils
were found to be stained by Ki-67 in the tumor site, show-
ing a proliferating state for these cells. These cells mostly
express pro-tumor N2 phenotype markers and can be
viewed as myeloid-derived suppressor cells (MDSCs),
which represent a heterogeneous group of immature mye-
loid cells comprising macrophages, monocytes, neutro-
phils, and DCs [37] or myeloid progenitor cells at different
stages of development that have been reported to be re-
cruited along with PMNs to sites of inflammation and
proliferate in tissue [38].
Interleukin-8 (IL-8), which is known as keratinocyte-
derived chemokine (KC) in the murine, is a proinflamma-
tory CXC chemokine associated with the neutrophil
chemotaxis and degranulation [24]. It is also reported to
be a transcriptional target of Ras Signaling, but its role in
Ras-induced tumorigenesis has not been fully defined [39].
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proliferation and neutrophil infiltration into the tumor
[40-42]. According to our previous study, the expression
of KC in the BALF of the CC-LR mice was higher com-
pared to the WT mice [15]. The application of curcumin,
which is a naturally occurring polyphenolic phytochemical
isolated from the rhizome of the medical plant Curcuma
longa, with non-specific anti-inflammatory effect, could
suppress lung tumor promotion partly by suppressing KC
production and subsequent inhibition of neutrophil re-
cruitment to the lung [16]. In the current study, KC level
was also suppressed by mLy-6G Ab in the non-NTHi-
exposed group.
The protein encoded by the CXCR2 gene is a member of
the G-protein couple receptor family. It is the receptor for
IL-8. This receptor mediates neutrophil migration to sites
of inflammation and is essential for neutrophil recruitment
[43,44]. There is a remarkable up-regulation of CXCR2 in
airway epithelial cells in COPD, and this correlates with
the increased number of neutrophils in the airways [45].
Neutrophil recruitment into tumors also appears to be
dependent on chemokines that bind to CXCR2 expressed
by neutrophils [40]. Furthermore, CXC chemokines are
potent promoters of angiogenesis, and mediate their
angiogenic activity via signal-coupling of CXCR2 on endo-
thelium [41,46,47]. It has recently been shown that
CXCR2 expression in tumor cells is a poor prognostic fac-
tor and promotes invasion and metastasis in lung adeno-
carcinoma [48]. We found that inhibiting CXCR2 by a
selective antagonist could efficiently suppress neutrophilic
inflammation and lung tumor progression. This was asso-
ciated with significant reduction in tumor cell proliferation
and angiogenesis. This is similar to the findings from other
groups showing that CXCR2 inhibition using a neutraliz-
ing antibody inhibits the progression of premalignant al-
veolar lesions by reducing vascular density in another
mouse model of lung cancer [49]. Analysis of the cyto-
kines and chemokines in the BALF of CC-LR mice
showed that the secretion of pro-inflammatory cytokines
(IL-6, IL-17, TGF-β) decreased after treatment with
CXCR2 inhibitor with further reduction in levels of N2
type markers, CCL-5. This was associated with decreased
expression of arginase 1, while the expression of iNOS in-
creased. These results indicate that CXCR2 inhibition not
only suppresses the recruitment of neutrophils but also
may shift their differentiation from a N2 phenotype to a
N1 phenotype. There was a much larger reduction in
angiogenesis with CXCR2 inhibition as opposed to neu-
trophil depletion with mLy-6G Ab treatment. This could
be due to inhibition of additive direct effect of CXCR2 axis
activation on tumor endothelial cells that leads to less
tumor angiogenesis.
Similar to mLy-6G Ab treatment, neutrophils in BALF
of NTHi-exposed mice were not affected by the CXCR2inhibitor, but it reduced the number of infiltrating neutro-
phils with MDSC/progenitor cell characteristics in the
lung parenchyma and tumor sites. Failure of the anti-
neutrophil Ab and CXCR2 inhibitor in inhibiting BALF
neutrophilic influx in response to repetitive exposure to
NTHi indicates involvement of other chemokines and in-
flammatory signaling pathways besides the IL-8/CXCR2
pathway in this phenomenon.
Products secreted from neutrophils, such as, reactive
oxygen species and proteinases, have defined and specific
roles in regulating tumor cell proliferation, angiogenesis,
and metastasis [34]. Among them, NE is generally consid-
ered the major effector of neutrophil function, making up
approximately 2% of the dry weight of a neutrophil [50]. It
contributes to cigarette smoke-induced emphysema in
mice [51]. NE KO mice are significantly protected from
the development of CS-induced emphysema and recruit-
ment of both neutrophils and macrophages. We have also
found that lack of NE reduces lung macrophages and in-
hibits lung cancer promotion in our K-ras mutant mouse
model indicating an essential promoting role for this en-
zyme in lung tumorigenesis. This is consistent with the
study from Houghton et al., where they found the similar
promoting effect for NE through degradation of IRS-1 in
another mouse model of lung cancer [52]. NE exposure
can activate PI3K/Akt pathway resulting in tumor cell pro-
liferation and survival [52]. Lack of NE in our K-ras mu-
tant model was associated with decreased proliferation
and increased apoptosis of tumor cells which could be sec-
ondary to lack of PI3K/Akt pathway activity in absence
of NE. Tumor regression was also accompanied with
decreased levels of TGF-β similar to the finding by Kang-
Yun et al., showing that NE up-regulates TGF-β gene ex-
pression and release via the MyD88/IRAK/NF-κB pathway
[53]. It has been previously shown that TANs were in-
volved in tumor angiogenesis by the production of proan-
giogenic factors such as VEGF and IL-8 [8], proteases
such as MMPs [54] and elastases [55]. We have also found
decreased expression of VEGF and numbers of CD31
positive cells in our K-ras mutant mouse with lack of NE,
indicating a role for NE in tumor angiogenesis. It has also
been shown that NE can cleave VEGF to generate a diffus-
ible VEGF fragments that stimulate inflammatory cell
recruitment and activation via VEGF receptor 1/Akt path-
way [56] that could be considered as a tumor promoting
mechanism of NE in our model. Similar to our findings
Wada et al. have demonstrated that NE released from acti-
vated neutrophils stimulates the growth and progression
of cancer cells by releasing the growth factors such as
VEGF on the cell surface and that sivelestat, a specific NE
inhibitor, blocks these processes [57].
It is known that K-ras induces the secretion of the
cytokine IL-6 in various epithelial cell types including
lung epithelial cells [58]. We have previously revealed
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STAT3 pathway in our K-ras induced mouse model of lung
cancer in absence and presence of COPD-like airway in-
flammation [59]. We further demonstrated that genetic ab-
lation of IL-6 results in significant tumor suppression in
this model in vivo, indicating an essential role for IL-6 in
lung cancer promotion in this model. Therefore, reduced
levels of IL-6 in response to neutrophil depletion, CXCR2
inhibition, or lack of NE could be considered as another
mechanism of tumor regression. However, this could simply
be a reflection of the reduced production of this cytokine
from K-ras mutant cells due to reduction in tumor burden.
Conclusions
Taken together, we confirmed that neutrophils play a
very important role in the promotion of lung cancer
which is strongly mediated through the IL-8/CXCR2
pathway and release of NE and development of a type 2
protumor microenvironment. This provides a baseline
for future clinical trials and/or prevention trials using
the IL-8/CXCR2 pathway or NE inhibitors in patients
with lung cancer and high risk COPD patients.
Materials and methods
Animals
CCSPCre/LSL-K-rasG12D mice (CC-LR) were generated as
previously described [15]. Briefly, this is a mouse generated
by crossing a mouse harboring the LSL-K-rasG12D allele
with a mouse containing Cre recombinase inserted into
the Clara cell secretory protein (CCSP) locus [15]. CC-LR
mice were crossed with neutrophil elastase (NE) knock out
(KO) mice [52,60], which were kindly provided by Dr.
Steven Shapiro (University of Pittsburgh) to generate
CC-LR-NEKO mice. All mice were housed in specific
pathogen-free conditions and handled in accordance
with the Institutional Animal Care and Use Committee of
M. D. Anderson Cancer Center. Mice were monitored
daily for evidence of disease or death.
NTHi lysate aerosol exposure
A lysate of NTHi strain 12 was prepared as previously de-
scribed [15], the protein concentration was adjusted to
2.5 mg/ml in phosphate buffered saline (PBS), and the lys-
ate was frozen in 10 ml aliquots at −80°C. To deliver the
lysate to mice by aerosol, a thawed aliquot was placed in
an AeroMist CA-209 nebulizer (CIS-US, Bedford, MA)
driven by 10 liter/min of room air supplemented with 5%
CO2 for 20 min.
Neutrophils depletion and CXCR2 inhibition
Neutrophils were depleted with the anti-neutrophils
antibody (Ab), mLy-6G (clone: RB6-8C5; Bio X Cell,
West Lebanon, NH, USA), 100ul at the concentration of
1 mg/ml per mouse, twice a week by intraperitoneal (i.p.)injection. CXCR2 was inhibited by using a selective inhibi-
tor, SB332235Z, 50 mg/kg orally, twice daily by gavage
(GSK, Brentford, UK).
Histochemistry
The tracheas of euthanized mice were cannulated with
PE-50 tubing and sutured into place. The lungs were in-
fused with 10% buffered formalin (Sigma, St. Louis, MO)
and then removed and placed in 10% buffered formalin
for 18 hours. Tissues then were transferred to 75% etha-
nol, embedded in paraffin blocks, and sectioned at 5-mm
thickness. The sections on glass slides were dried at 60°C
for 15 minutes and then were deparaffinized and stained
with hematoxylin and eosin (H&E) by incubating the tis-
sues in Harris hematoxylin (Sigma) followed by serial
eosin (Sigma) and graded ethanol steps. The H&E-stained
slides were examined by a pathologist blinded to genotype
and treatment, and the proliferative lesions of the lungs
were evaluated in accordance with the recommendations
of the Mouse Models of Human Cancer Consortium [61].Immunohistochemistry
Previously sectioned lung samples on slides were immu-
nohistochemically (IHC) stained and evaluated for ex-
pression of Ki-67 (1:200; ab16667; abcam, MA, USA),
P40 (1:100; MCA771G; Serotec, Oxford, UK), CD31
(1:10, 550274, BD Biosciences, CA, USA), VEGF (1:500;
sc-152, Santa Cruz, CA, USA), cleaved caspase-3 (1:500,
ab13847, abcam), Anti-Ly6g (1:100, ab25377, abcam),
Arginase 1 (1:100, Thermo scientific, PA5-22009) DAPI
(Signa, D9564-10MG), Alexa Fluor 488 Dye and Alexa
Fluor 594 (Invitrogen). All antibodies reacted with
mouse antigens. Heat-induced antigen retrieval was per-
formed using 10 mmol/L of citrate buffer (pH 6) in a
pressure cooker for 20 min. Endogenous peroxidase was
quenched with 3% hydrogen peroxide for 30 min at
room temperature. Blocking was performed with non-
immune normal serum. Immunoreactivity for immuno-
histochemistry was detected using biotinylated IgG
secondary antibodies specific for each primary antibody
followed by incubation with ABC kit (Vector Laboratory,
Burlingame, CA) for 30 min, and stained with diamino-
benzidine chromogenic substrate for 4–10 min. Slides
were counter-stained with Harris hematoxylin in for
30 sec, followed by dehydration and mounted with cyto-
seal 60 (ThermoFisher Scientific, Cheshire, UK). Images
were obtained by an OLYMPUS BX 60 inverted micro-
scope at ×4, ×20 or ×40 magnification with Image-Pro
Plus, version 4.5.1.22. The numbers of labeled positive
cells for any of these markers were quantitated as a frac-
tion of total tumor nuclei per high power field (40×) in
10 fields from three mice of each group. Results were
expressed as percentage of positive cells ± SE.
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On the first day after the final NTHi exposure, animals
were euthanized by i.p. injection of a lethal dose of avertin
(Sigma). In all mice (n = 8 per group per time point), lung
surface tumor numbers were counted and then in some of
them (n = 8 per group per time point), the lungs were pre-
pared for histologic analysis as described above. In other
mice (n = 8 per group per time point), bronchoalveolar lav-
age fluid (BALF) was obtained by sequentially instilling
and collecting 2 aliquots of 1 mL PBS through a tracheos-
tomy cannula. Total leukocyte count was determined using
a hemacytometer, and cell populations were determined by
cytocentrifugation of 300 mL of BALF followed by Wright-
Giemsa staining. The remaining BALF (1,400 mL) was
centrifuged at 1,250 × g for 10 min, and supernatants were
collected and stored at −80°C.
Cytokines and chemokines measurement
The levels of KC, TNF, IL-6, IL-10, IL-17A, CCL2,
CCL5 and VEGF in the BALF were assessed using
MCYTOMAG-70 K assay (Millipore, St Charles, MO),
according to the manufacturer’s instructions). Due to
reagent incompatibilities, TGF-β was assayed separately
from the other cytokines using the TGFB-64 K-01
(Millipore, MO, USA) assay. Data were collected using a
Luminex 100 (Luminex Corporation, TX, USA). Standard
curves were generated using a 5-parameter logistic curve-
fitting equation weighted by 1/y (StarStation V 2.0; Applied
Cytometry Systems, CA, USA). Each sample reading was
interpolated from the appropriate standard curve.
Quantitative RT-PCR analysis
Total RNA was isolated from whole lung according to the
TRIzol reagent protocol (Invitrogen, NY, USA) and puri-
fied by E.Z.N.A. total RNA kit I (OMEGA, GA, USA).
Reverse transcription PCR was performed using the
qScript cDNA SuperMix (Quanta biosciences, MD, USA).
Real-time PCR was carried out according to a standard
protocol using the PerfeCTaFast Mix II (Quanta) with the
TaqMan probe for arginase 1 and iNOS (ABI, NY, USA),
and products measured on an ABI Viia 7 PCR system
(ABI). Relative expression of each gene was calculated and
graphed for comparison among the treatment groups.
GAPDH RNA was measured for reference.
Western blot analysis
Total proteins were prepared from each group of mouse
lungs. Lung samples were removed and immediately
placed in RIPA buffer and a protease inhibitor mixture.
The samples were then homogenized and centrifuged at
14000 g for 20 min at 4°C. The supernatants were col-
lected as the total proteins. Equal amounts (40 μg) of
the total proteins were boiled for 5 min in the presence
of loading buffer, loaded on each lane, and separated by10% SDS-PAGE. The gels were then transferred to nitrocel-
lulose membranes. Equal amounts of protein loading for
each lane was checked by Ponceau (Sigma Chemical Co.,
MO, USA) staining. The anti-arginase 1 (Thermo Scientific,
clone PA5-22009, MA, USA) antibody was diluted to the
concentration according to commercial recommendations
(1:1000). Immunoreactive bands were detected with Pierce
ECL Western Blotting Substrate (Pierce, IL, USA).
Statistical methods
Summary statistics for cell counts in BALF, IHC positive
cells in lung tissue, and mRNA expression were com-
puted within treatment groups, and analysis of variance
with adjustment for multiple comparisons was con-
ducted to examine the differences between the control
group and each of the treatment groups in the presence
or absence of NTHi exposure. For tumor counts, com-
parisons of groups were made using Student’s t test.
Differences were considered significant for P < 0.05.
Additional files
Additional file 1: Figure S1. (A) Real-time Q-PCR analysis of RNA
extracted from whole lung tissue for relative mRNA expression of iNOS
(normalized to GAPDH expression level, mean ± SE). (B) Representative
immunofluorescence staining showing Ly6G + and Arginase 1+ double
positive neutrophils after exposure to NTHi (Scale bar, 50 μm). (C)
Representative immunofluorescence staining showing P40+ and Ki67+
double positive neutrophils with and without mLy-6G treatment after
NTHi exposure (Scale bar, 50 μm).
Additional file 2: Figure S2. (A) Real-time Q-PCR analysis of RNA extracted
from whole lung tissue for relative mRNA expression of iNOS (normalized to
GAPDH expression level, mean ± SE). (B) Representative immunofluorescence
staining showing P40+ and Ki67+ double positive neutrophils with and
without SBZ treatment after NTHi exposure (Scale bar, 50 μm).
Additional file 3: Figure S3. (A) Lung surface tumor number in CC-LR
and CC-LR-NEKO mice afxxter NTHi exposure (N = 4). (B) Total and
lineage-specific leukocyte number in BALF of NTHi-exposed CC-LR and
CC-LR-NEKO mice collected 1 day after last NTHi aerosol exposure at the
age of 14 weeks (mean ± SE). (C) Histopathological appearance of lung
tissue in CC-LR and CC-LR-NEKO after NTHi exposure.
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